Tandem Mobi gets FDA approval
By HME News Staff
Updated 10:08 AM CDT, Thu July 13, 2023
SAN DIEGO – Tandem Diabetes Care has received U.S. Food and Drug Administration clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up. The Tandem Mobi is fully controllable from a mobile app. “Testing the limits of pump miniaturization, Tandem Mobi joins the t:slim X2 pump in our family of insulin delivery solutions bringing new options in wearability, the flexibility to disconnect, and full phone control,” said John Sheridan, president and CEO. “Through this expansion, we are delivering on our commitment to bring greater choice, along with the proven benefits of Tandem’s technology, to more people living with diabetes.” The Tandem Mobi features a 200-unit insulin cartridge and an on-pump button that provides an alternative option to phone control for bolusing insulin. Additional features include multiple wear options, detachable infusion sets, automated insulin delivery and mobile app control. A limited release of Tandem Mobi is expected to start in late 2023 with full commercial availability planned in early 2024.
Comments